Utilizing a combinatorial therapeutic strategy, stealth liposomes modified with an EphA2-binding homing peptide (YSA-LP) in conjunction with Doxorubicin (DOX) have demonstrated enhanced efficacy against cancer cells. Here, EPHA2 is linked to cancer.